New trial
Phase 1 PF-08046031 anti-CD228 ADC trial for advanced melanoma and solid tumors.
- Trial ID
- NCT06799533 on ClinicalTrials.gov
- Cancer type
- Other Solid Tumors
- Stage of research
- First-in-human
- Location
- 4 Locations
- Published in
- New in Oncology - July 3, 2025
This open-label Phase 1 study evaluates PF-08046031 as monotherapy in adults with metastatic melanoma and other advanced solid tumors lacking approved treatment options. The trial, conducted by Pfizer at sites including Denver, Santa Monica, Orlando, and Los Angeles, aims to determine safety, dosing, and early signs of anti-tumor activity.
More in multiple solid tumors
-
Trial result · Oct 15, 2026 · NCT04985604
Tovorafenib (type II RAF inhibitor; BRAF/CRAF) drives 43% ORR in BRAF/RAF1-altered R/R solid tumors -
New trial · Oct 15, 2026 · NCT07819136
Phase 1/2 ZINNIA tests REC-7735, a PIK3CA H1047R-selective inhibitor, across advanced solid tumors -
New trial · Oct 15, 2026 · NCT07843550
Phase 1/2 larotrectinib plus pembrolizumab tests TRK inhibition after checkpoint failure in lung adenocarcinoma and melanoma -
New trial · Oct 15, 2026 · NCT07832630
Phase 2 saruparib tests PARP1 inhibition in HRD-signature-positive solid tumors without prior platinum resistance -
New trial · Oct 15, 2026 · NCT07811297
Phase 1b/2a catequentinib tests angiogenesis blockade alone and in combinations across four solid-tumor settings